Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
Sept 22 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
IONIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF ZILGANERSEN IN ALEXANDER DISEASE
IONIS PHARMACEUTICALS INC - PLANS NDA SUBMISSION FOR ZILGANERSEN IN Q1 2026
IONIS PHARMACEUTICALS INC - ZILGANERSEN 50 MG SHOWS SIGNIFICANT STABILIZATION IN GAIT SPEED
IONIS PHARMACEUTICALS INC - ZILGANERSEN SHOWS BENEFIT IN SECONDARY ENDPOINTS
IONIS PHARMACEUTICALS INC - ZILGANERSEN SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE
IONIS PHARMACEUTICALS INC: EVALUATING POTENTIAL TO INITIATE AN EXPANDED ACCESS PROGRAM (EAP) IN U.S.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








